Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point

Parkinsonism and Related Disorders

Volumn 13, Issue SUPPL. 3, 2007, Pages

  Bartus, Raymond T ^a   Herzog, Christopher D ^a   Bishop, Kathie ^a   Ostrove, Jeffrey M ^a   Tuszynski, Mark ^b   Kordower, Jeffrey H ^c   Gasmi, Mehdi ^a  

^a Ceregene Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Disease progression; Neuronal restoration; Neuroprotection; Neurotrophic factors; Neurturin

Indexed keywords

CERE 120; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; GENE VECTOR; HUMAN; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEUROPEPTIDES; NEURTURIN; PARKINSON DISEASE;

EID: 38949196405     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(08)70052-X     Document Type: Article

References (36)

1. Kordower J., Palfi S., Chen E., Ma S., Sendera T., Cochran E., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46 (1999) 419-424
2. Nutt J., Burchiel K., Comella C., Jankovic J., Lang A., Laws Jr. E., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
3. Eriksdotter Jönhagen M., Nordberg A., Amberla K., B̈ackman L., Ebendal T., Meyerson B., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9 (1998) 246-257
4. Day-Lollini P., Stewart G., Taylor M., Johnson R., and Chellman G. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 145 (1997) 24-37
5. Hovland Jr. D., Boyd R., Butt M., Engelhardt J., Moxness M., Ma M., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 35 (2007) 676-692
6. Salvatore M., Ai Y., Fischer B., Zhang A., Grondin R., Zhang Z., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202 (2006) 497-505
7. Raper S., Chirmule N., Lee F., Wivel N., Bagg A., Gao G., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Gen Metab 80 (2003) 148-158
8. Kohn D., Sadelain M., and Glorioso J. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3 (2003) 477-488
9. Bartus R. Neurotrophic factors: can the degenerating brain be induced to heal itself?. Neurobiol Aging 10 (1989) 513
10. Hefti F., Hartikka J., and Knusel B. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol Aging 10 (1989) 515-533
11. Kirik D., Rosenblad C., and Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci. 12 (2000) 3871-3882
12. Gash D., Zhang Z., Cass W., Ovadia A., Simmerman L., Martin D., et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 363 (1995) 345-358
13. Maswood N., Grondin R., Zhang Z., Stanford J., Surgener S., Gash D., et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23 (2002) 881-889
14. Kirik D., Rosenblad C., Bjorklund A., and Mandel R. Long-term rAAV- mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20 (2000) 4686-4700
15. Choi-Lundberg D., Lin Q., Schallert T., Crippens D., Davidson B., Chang Y., et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154 (1998) 261-275
16. Kordower J., Emborg M., Bloch J., Ma S., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
17. Lang A., Gill S., Patel N., Lozano A., Nutt J., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466
18. Gill S., Patel N., Hotton G., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
19. Slevin J., Gerhardt G., Smith C., Gash D., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line- derived neurotrophic factor. J Neurosurgery 102 (2005) 216-222
20. Sherer T., Fiske B., Svendsen C., Lang A., and Langston J. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 21 (2006) 136-141
21. Morrison P., Lonser R., and Oldfield E. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 107 (2007) 74-83
22. Bartus R. Drug delivery to the brain: The problem lurking behind the problem. Neurobiol Aging 10 (1989) 621
23. Bartus R. The blood-brain barrier as a target for pharmacological modulation. Curr Opin Drug Disc Dev 2 (1999) 152-157
24. Longo F., and Massa S. Neurotrophin receptor-based strategies for Alzheimer's disease. Curr Alzheimer Res 2 (2005) 167-169
25. Gasmi M., Herzog C., Brandon E., Cunningham J., Ramirez G., Ketchum E., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 15 (2007) 62-68
26. Kaplitt M., Feigin A., Tang C., Fitzsimons H., Mattis P., Lawlor P., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
27. Arvanitakis Z, Tuszynski MH, Potkin S, Bartus RT, Bennett D. A Phase I Clinical trial of CERE-110 (AAV-NGF) gene delivery in Alzheimer's disease. American Academy of Neurology Annual Meeting, 2007, Boston, MA.
28. Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, et al. Expression, bioactivity, and safety 1 year following AAV2- mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease. J Neurosurg, in press.
29. Herzog CD, Dass B, Gasmi M, Bakay RA, Stansell 3rd J, Tuszynski MH, et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-Neurturin) following delivery to the monkey striatum. Mol Ther, in press.
30. Gasmi M., Brandon E., Herzog C., Wilson A., Bishop K., Hofer E., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE- 120 for Parkinson's disease. Neurobiol Dis 27 (2007) 67-76
31. Herzog C., Dass B., Holden J., Stansell III J., Gasmi M., Tuszynski M., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22 (2007) 1124-1132
32. Wilson A, Hofer EK, Goulart A, Gasmi M, Bishop KM, Herzog CD, et al. Bioactivity and safety of intrastriatal CERE-120 (AAV2-NTN) in aged Fischer 344 rats. Neurobiol Aging, in press.
33. Kordower J., Herzog C., Dass B., Bakay R., Stansell III J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60 (2006) 706-715
34. st Annual Meeting, 2006, Chicago, IL.
35. th Annual Meeting, 2007, Washington, DC.
36. Bartus R., Ostrem J., Verhagen Metman L., Starr P., Larson P., Bakay R., et al. CERE-120 (AAV-Neurturin) for Parkinson's disease: From concept to clinical testing and beyond (2007), American Society of Gene Therapy Annual Meeting, Seattle, WA